Literature DB >> 6820110

The long-term skeletal effects of EHDP in dogs.

L Flora, G S Hassing, G G Cloyd, J A Bevan, A M Parfitt, A R Villanueva.   

Abstract

Disodium hydroxymethanediphosphonic acid was administered subcutaneously (s.c.) to adult beagle dogs for 1 to 2 years at various dose levels to determine its skeletal effects when given chronically. The effects were followed densitometrically, radiographically and by making histomorphometric measurements in sequential rib biopsies. At low doses (0.1 and 0.5 mg/kg/day s.c.) EHDP caused a time-and-dose dependent reduction in the percentage of bone surfaces with active mineralization, a reduction in mineralization rates, a reduction in resorption spaces but no changes in osteoid seam widths. No treatment related bone fractures were noted at the 0.1 mg/kg/day level, while at 0.5 mg/kg/day, fracture incidence appeared slightly increased. At higher doses (2-10 mg/kg/day), there was also a reduction in the number of resorption spaces, but mineralization activity was totally blocked, osteoid seams became thickened and fracture incidence was markedly increased. In one group of animals, EHDP treatment was discontinued after one year of dosage at 5 mg/kg/day given subcutaneously. In these animals, mineralization activity reappeared within 3 months, but osteoid seams remained thickened until 7 months post-treatment. These data indicate that EHDP can have profound effects on bone remodeling in the dog but that these effects are dose-and-time-dependent and they appear to be reversible.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6820110     DOI: 10.1016/0221-8747(81)90045-x

Source DB:  PubMed          Journal:  Metab Bone Dis Relat Res        ISSN: 0221-8747


  12 in total

Review 1.  The aging cortex: to crack or not to crack.

Authors:  Karl J Jepsen
Journal:  Osteoporos Int       Date:  2003-08-29       Impact factor: 4.507

Review 2.  Adverse effects of bisphosphonates. A comparative review.

Authors:  S Adami; N Zamberlan
Journal:  Drug Saf       Date:  1996-03       Impact factor: 5.606

Review 3.  Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease.

Authors:  H Fleisch
Journal:  Drugs       Date:  1991-12       Impact factor: 9.546

4.  Short term high doses of etidronate in Paget's disease of bone.

Authors:  J A Kanis; R E Gray; S A Murray; N A Hamdy; G H Urwin
Journal:  Br Med J (Clin Res Ed)       Date:  1986-06-21

Review 5.  Bisphosphonates in osteoporosis?

Authors:  O L Bijvoet; R Valkema; C W Löwik; S E Papapoulos
Journal:  Osteoporos Int       Date:  1993       Impact factor: 4.507

Review 6.  Safety of long-term bisphosphonate therapy for the management of osteoporosis.

Authors:  E Michael Lewiecki
Journal:  Drugs       Date:  2011-04-16       Impact factor: 9.546

7.  Continuous alendronate treatment throughout growth, maturation, and aging in the rat results in increases in bone mass and mechanical properties.

Authors:  J A Guy; M Shea; C P Peter; R Morrissey; W C Hayes
Journal:  Calcif Tissue Int       Date:  1993-10       Impact factor: 4.333

Review 8.  Use of bisphosphonates for the treatment of stress fractures in athletes.

Authors:  Yosuke Shima; Lars Engebretsen; Junji Iwasa; Katsuhiko Kitaoka; Katsuro Tomita
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2008-12-02       Impact factor: 4.342

Review 9.  Perspective on post-menopausal osteoporosis: establishing an interdisciplinary understanding of the sequence of events from the molecular level to whole bone fractures.

Authors:  L M McNamara
Journal:  J R Soc Interface       Date:  2009-10-21       Impact factor: 4.118

Review 10.  Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy.

Authors:  R G G Russell; N B Watts; F H Ebetino; M J Rogers
Journal:  Osteoporos Int       Date:  2008-06       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.